年度业绩：2025YTD（截至 2025.12.12），公募沪深 300 指增平均超额收益 -0.24%，实现正超额收益的基金占比 40.68%；公募中证 A500 指增平均超 额收益 1.04%，实现正超额收益的基金占比 75.00%；公募中证 500 指增平 均超额收益 0.64%，实现正超额收益的基金占比 58.46%；公募中证 1000 指增平均超额收益 7.52%，实现正超额收益的基金占比 89.13%；公募主动 量化基金平均收益 26.64%，实现正收益的基金占比 97.51%；公募股票市场 中性基金平均收益 1.03%，实现正收益的基金占比 59.09%。 金工量化周报 大盘指增和中小盘指增超额收益出现分化 量化基金业绩跟踪周报（2025.12.08-2025.12.12） 核心结论 周度业绩：本周（2025.12.08-2025.12.12），公募沪深 300 指增平均超额收 益 0.21%，实现正超额收益的基金占比 71.62%；公募中证 A500 指增平均 超额收益-0.04%，实现正超额收益的基金占比 45.59%；公募中证 500 指增 平均超额收益-0.44%，实现正超额收益的基金占 ...

Investment Rating - The report gives a "Buy" rating for the company, Hangya Technology (688510.SH), with a target price of 31.2 yuan based on a 40x valuation for 2026 [2][4][15]. Core Insights - Hangya Technology focuses on precision forging technology, specializing in key components for aircraft engines and medical orthopedic implants. The company has established a strong position in the aircraft engine parts sector since its listing on the Sci-Tech Innovation Board in 2020 [1][4][17]. - The company reported revenues of 530 million yuan and a net profit of 78 million yuan for the first three quarters of 2025, reflecting a year-on-year increase of 1.95% in revenue but a decrease of 16.04% in net profit [1][31]. - The demand for international commercial aircraft engines is increasing, and Hangya Technology has positioned itself advantageously to meet this demand by becoming a reliable supplier for major players like CFM [1][39][44]. Summary by Sections 1. Company Overview - Hangya Technology is centered on precision forging technology, focusing on critical components for aircraft engines and medical implants. The company has made significant advancements in manufacturing techniques since its establishment in 2013 [1][17][20]. 2. Market Demand and Positioning - The international commercial aircraft engine market is characterized by a few dominant players, with CFM leading in delivery volumes. Hangya Technology has successfully positioned itself as a key supplier amid supply chain disruptions [1][39][44]. - CFM is actively seeking domestic suppliers to alleviate supply chain pressures, which presents opportunities for Hangya Technology to expand its market share [1][45][47]. 3. Growth Drivers - The company is experiencing growth across multiple sectors, including domestic aircraft engines, gas turbines, and medical products. Collaborations with major clients like GE and domestic aerospace firms are expected to drive future revenue growth [1][2][11][57]. - The domestic aviation market is projected to grow significantly, with increasing demand for new aircraft, which will benefit Hangya Technology's operations [1][57][59]. 4. Financial Projections - Revenue forecasts for Hangya Technology indicate growth from 817 million yuan in 2025 to 1.512 billion yuan by 2027, with corresponding net profits expected to rise from 130 million yuan to 290 million yuan during the same period [2][15][31]. - The company's earnings per share (EPS) are projected to increase from 0.51 yuan in 2025 to 1.13 yuan by 2027, reflecting strong growth potential [2][15]. 5. Strategic Collaborations - Hangya Technology has established strategic partnerships with key industry players, enhancing its production capabilities and market reach. The collaboration with CFM and other international clients is expected to solidify its position in the market [1][49][54].

证券研究报告 核心结论 2）模型侧，我们认为多模态能力从根本上降低了大模型的理解、交互和解决实际问题的门槛，从而将其应用范围从 文字世界，极大地拓展至我们身处的这个物理世界，重点关注大模型多模态能力提升。 从"+AI"到"AI+"，AI巨轮破浪前行 ——2026年计算机行业年度策略 西部证券研发中心 2025年12月12日 分析师：郑宏达 S0800524020001 邮箱地址：zhenghongda@research.xbmail.com.cn 分析师：谢忱 S0800524040005 邮箱地址：xiechen@research.xbmail.com.cn 分析师：李想 S0800525040006 邮箱地址：lixiang@research.xbmail.com.cn 分析师：卢可欣 S0800525080006 邮箱地址：lukexin@research.xbmail.com.cn 2025年回顾：1）回顾2025年，年初以DeepSeek为代表的国内AI大模型取得较大突破，计算机行业于2月份走出一 轮显著跑赢大盘的独立上涨行情。4月，外部冲击与内部估值压力形成共振，导致板块出现一轮快速回调。经过调整 ...

国内政策点评报告 内外统筹、注重质效、问题导向、持续摸索 中央经济工作会议精神解读 核心结论 中央经济工作会议 12 月 10 日至 11 日在北京举行。中共中央总书记、国家 主席、中央军委主席习近平在重要讲话中总结 2025 年经济工作，分析当前 经济形势，部署 2026 年经济工作。今年中央经济工作会议的整体思路可以 概括为内外统筹、注重质效、问题导向、持续摸索。对于备受关注的地产政 策有所提及，但包括地产在内的风险应对工作在任务部署从去年的居中位置 下移至末尾，可见当前经济总体风险较去年有所改善。以下是四点对于会议 精神的具体分析： 三是问题导向。如"推动投资止跌回稳"、"努力稳定新出生人口规模"、"要 树立和践行正确政绩观……完善差异化考核评价体系"等表述体现出鲜明的 问题导向，以及针对问题加以解决的信念与决心，后续政策值得关注。 四是持续摸索。在经济工作指导思想"五个必须"之前，即提及"会议认为， 通过实践，我们对做好新形势下经济工作又有了新的认识和体会"，对去年 提及的"深化对经济工作的规律性认识"有意呼应，体现出迎难而上、创新 探索的精神。 具体工作方面，地产政策再提"去库存"。这是继 2015 ...

攻守兼备，穿越周期 证券研究报告 -餐饮行业深度研究报告 西部证券研发中心 2025年12月12日 分析师 | 肖燕南 S0800525070002 分析师 | 田地 S0800525050004 分析师 | 于佳琦 S0800525040008 核心结论 风险提示：食品安全风险；消费力持续下行风险；行业竞争加剧风险。 | 行业评级 | 超配 | | --- | --- | | 前次评级 | -- | | 评级变动 | 首次 | 近一年行业走势 -24% -18% -12% -6% 0% 6% 12% 2024-12 2025-04 2025-08 酒店餐饮 沪深300 | 相对表现 | 1个月 | 3个月 | 12个月 | | --- | --- | --- | --- | | 酒店餐饮 | -5.41 | -2.47 | -17.33 | | 沪深300 | -2.02 | 0.67 | 13.00 | 请务必仔细阅读报告尾部的投资评级说明和声明 2 一、服务消费政策主要方向，餐饮有望重点受益 • 消费提振重点明确，"服务消费"政策持续加码。今年9月商务部等提出扩大服务消费5大方向19条具体 措施，餐饮为 ...

Group 1: Pharmaceutical Industry Insights - The 2026 pharmaceutical industry strategy report highlights a reversal in the market, driven by innovative drugs, with significant gains across various secondary sectors, particularly in Hong Kong where innovative drugs saw an increase of over 80% year-to-date [6][8] - Key catalysts for innovative drugs include policy support and successful business development (BD) transactions, with notable deals exceeding $1 billion validating the international competitiveness of Chinese innovative drugs [6][7] - A significant policy reform in October 2025 initiated a dual-track system for medical insurance, addressing the high-value innovative drugs' inclusion challenges, which is expected to guide commercial insurance to cover these gaps [6] Group 2: Company-Specific Updates - Yixin Group (2858.HK) has been included in the Hong Kong Stock Exchange Technology 100 Index, which is expected to enhance liquidity, and has renewed a strategic cooperation agreement for used car services, reflecting confidence in the growing demand for this segment [10][11] - The company reported a robust Q3 performance with a total of 235,000 auto financing transactions, a year-on-year increase of 22.6%, outperforming the market growth rate of approximately 11% [11] - Yixin Group's financial technology business has shown significant growth, with financing facilitated through its platform reaching approximately 114 billion yuan, a year-on-year increase of about 102% [11] Group 3: Electronic Sector Developments - Fuzhicheng Technology (002222.SZ) has exceeded revenue expectations, with a projected revenue growth to 11.15 billion yuan in 2025, and net profit expected to reach 3.02 billion yuan [15] - The company maintains a strong position in the ultra-precision optics sector, with its subsidiary achieving significant advancements and a revenue increase of 73.66% in H1 2025 [14] - Naxin Microelectronics (688052.SH) has successfully completed its H-share IPO, marking a critical step in its internationalization, with projected revenues of 33.01 billion yuan in 2025 [19]

Investment Rating - The investment rating for the company is "Buy" [5]. Core Insights - The company maintains a solid position in its traditional business, with significant R&D investments yielding fruitful results. It is the largest global producer of LBO and BBO crystals and components, holding the number one market share globally. The precision optical products segment has achieved mass production of new prism gratings for high-speed optical network dynamic control modules, with performance metrics reaching international advanced levels, making it a key supplier for leading domestic and international companies [1][5]. - The company has targeted high-end laser device markets to address the bottleneck of imported core components, successfully breaking the monopoly of foreign suppliers with its self-developed acousto-optic and magneto-optic devices. In the first three quarters of 2025, the company achieved revenue of 842 million yuan, a year-on-year increase of 26.62%, and a net profit attributable to the parent company of 218 million yuan, up 29.75% year-on-year, with Q3 2025 marking record highs for both revenue and profit [1]. - The company’s subsidiary, Zhiqi Photonics, has made significant progress in the ultra-precision optical field, achieving a revenue of 49.05 million yuan in the first half of 2025, a year-on-year increase of 73.66%, and successfully turning a profit. The company is well-positioned to capitalize on future opportunities in ultra-precision optics [2][3]. Financial Projections - Revenue projections for the company are estimated at 1.115 billion yuan for 2025, 1.339 billion yuan for 2026, and 1.503 billion yuan for 2027, with corresponding net profits of 302 million yuan, 406 million yuan, and 494 million yuan respectively. The company is expected to see steady growth across its various business segments [3][4]. - The projected growth rates for revenue are 27.3% in 2025, 20.1% in 2026, and 12.2% in 2027, while net profit growth rates are expected to be 38.0% in 2025, 34.6% in 2026, and 21.6% in 2027 [4]. Key Data - The company’s earnings per share (EPS) is projected to be 0.64 yuan in 2025, 0.86 yuan in 2026, and 1.05 yuan in 2027. The price-to-earnings (P/E) ratio is expected to decrease from 99.9 in 2025 to 61.0 in 2027, indicating improving valuation metrics [4][10]. - The company’s return on equity (ROE) is projected to improve from 17.8% in 2025 to 20.8% in 2027, while the gross profit margin is expected to stabilize around 56.5% in 2025 and 56.7% in 2027 [10].

公司点评 | 易鑫集团 纳入港交所科技 100 指数、Q3 运营数据表现优异 证券研究报告 2025 年 12 月 11 日 易鑫集团（2858.HK）业务更新点评 事件：12/9，港交所推出港交所科技 100 指数，公司为成分股；12/8，易鑫 集团公布与精真估续订二手车服务战略合作协议。此外，公司于 12/2 公布 Q3 运营数据。 与腾讯系绑定持续深化，纳入港交所科技 100 指数，流动性有望进一步改善。 公司近日发布公告，宣布与精真估续订二手车服务战略合作协议。腾讯为公 司控股股东，精真估为腾讯的附属公司，公司与腾讯系合作持续深化。续订 协议下，精真估将继续为公司提供二手车估值及相关服务，公司将支付相应 的服务费。现有协议的现有年度上限为 5000 万元，续订后新年度上限提升 至 6000 万元，上限提升体现出公司对二手车业务需求增长的信心。另外， 公司纳入港交所科技 100 指数，港交所科技 100 是港交所推出的首只港股指 数，追踪 100 间在香港交易所上市的市值最大的科技公司的表现，港交所已 授权易方达基金在内地推出追踪港交所科技 100 指数的 ETF，公司流动性有 望进一步提升。 Q3 运 ...

Group 1 - The core viewpoint of the report highlights that the pharmaceutical industry in China is experiencing a reversal in 2025, driven by innovative drugs, with significant benefits observed in the CXO and upstream supply chain sectors, particularly in the Hong Kong stock market where innovative drugs have seen a rise of over 80% year-to-date [1][4] - The report emphasizes that the core catalyst for innovative drugs comes from policy support and the realization of business development (BD) opportunities abroad, with notable transactions exceeding 1 billion USD, validating the international competitiveness of Chinese innovative drugs [1][2] - A significant reform in the payment sector is underway, with the introduction of a dual-track system for medical insurance, allowing for the inclusion of high-value innovative drugs in commercial insurance, addressing the gap in coverage for expensive treatments [1][2] Group 2 - The report indicates a rapid growth trend in the number of license-out transactions by Chinese pharmaceutical companies, with total upfront payments reaching 6.298 billion USD, a 53% year-on-year increase, and total transaction amounts reaching 118.862 billion USD, a 125% increase [2] - Looking ahead to 2026, the report suggests a shift from "BD-driven" to "data-driven" investment in innovative drugs, emphasizing the importance of clinical data validation and commercial capabilities for revenue growth [2] - Recommended stocks for investment include Heng Rui Medicine, Kelun-Biotech, and Teva Biopharmaceuticals, among others, while companies like Kangfang Biotech and Innovent Biologics are suggested for further attention [2][3] Group 3 - The overall profitability of the pharmaceutical sector remains stable, with a gradual improvement in the profitability of the pharmaceutical manufacturing industry, despite a slight decline in revenue growth [11][15] - The report notes a significant divergence within the industry, with the medical services sector performing well, while the profits of the biopharmaceutical sector have seen a substantial decline [28][29] - The report highlights that the medical insurance fund's income and expenditure growth rates are stabilizing, indicating a long-term trend towards cost control in medical insurance, which is essential for the sustainable development of the innovative drug industry [31][36]

Investment Rating - The investment rating for the company is "Buy" [3][5]. Core Insights - The company successfully listed on the Hong Kong Stock Exchange on December 8, 2025, with a maximum share price of 116 HKD, marking a significant step in its internationalization process [1][5]. - The company's revenue structure for Q1-Q3 2025 shows that automotive electronics account for 34%, the general energy sector for 53%, and consumer electronics for 13% [2]. - The automotive electronics segment has seen a quarterly growth in Q3 2025, driven by new applications in body electronics, smart lighting, and thermal management, with the per-vehicle value exceeding 1300 RMB [2]. - The general energy sector has experienced significant growth, particularly in the photovoltaic and energy storage markets, supported by AI server demand [2]. - The consumer electronics segment focuses on emerging scenarios such as robotic vacuum cleaners and smart home appliances, benefiting from the acquisition of Maiguan [2]. Financial Projections - Revenue projections for 2025-2027 are estimated at 3.301 billion, 4.342 billion, and 5.066 billion RMB, respectively, with a growth rate of 68.4% in 2025 [3][4]. - The net profit attributable to the parent company is projected to be -133 million, 203 million, and 549 million RMB for 2025-2027, indicating a significant recovery in profitability [3][4]. - The earnings per share (EPS) is expected to improve from -0.82 RMB in 2025 to 3.40 RMB in 2027 [4].